The ABILITY-1 (A Beta-only IL-2 ImmunoTherapY) is a global Phase 1/2 study evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of MDNA11, both as single agent and in combination with a PD-1 inhibitor, in pre-treated patients with advanced...
pharmacokinetics, pharmacodynamics, and anti-tumor activity of various doses of intravenously administered MDNA11 in patients with advanced, relapsed, or refractory solid tumors. The trial includes an MDNA11 monotherapy arm, as well ...
Evidence of clinical activity includes SD in 6 of 19 patients in addition to a durable PR in a PDAC patient. Data analysis is ongoing to inform RDE selection. Acknowledgements We are grateful to all patients participating in this study. Trial Registration NCT: 05086692 Reference Merchant R, ...
Background High dose (HD) IL-2 has shown durable tumor response in a subset of metastatic melanoma and renal cell carcinoma (RCC), but its clinical utility is limited by need for frequent administration, undesirable activation of immune suppressive Tregs, and severe toxicities. MDNA11 is an ...
(A Beta-only IL-2 ImmunoTherapY) trial is a first-in-human phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD) effects, and preliminary clinical activity of MDNA11 as monotherapy and in combination with an immune checkpoint inhibitor in patients with ...